[1]姚 菲 王家晓 李春姗 石 玮.解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者的临床疗效观察[J].大众科技,2020,22(12):57-60.
　Clinical Observation of Jiedu Fuzheng Decoction Combined with EGFR TKIs on Elderly Patients with Advanced Lung Cancer[J].Popular Science & Technology,2020,22(12):57-60.
点击复制

解毒复正汤联合EGFR-TKIs对老年晚期 肺癌患者的临床疗效观察()
分享到：

《大众科技》[ISSN:1008-1151/CN:45-1235/N]

卷:
22
期数:
2020年12
页码:
57-60
栏目:
医药与卫生
出版日期:
2020-12-20

文章信息/Info

Title:
Clinical Observation of Jiedu Fuzheng Decoction Combined with EGFR TKIs on Elderly Patients with Advanced Lung Cancer
作者:
姚 菲 王家晓 李春姗 石 玮
（广西中医药大学第一附属医院，广西 南宁 530023）
关键词:
解毒复正汤; EGFR-TKIs; 晚期肺癌; 老年肺癌; 回顾性分析
Keywords:
Jiedu Fuzheng decoction EGFR-TKIs advanced lung cancer senile lung cancer retrospective analysis
文献标志码:
A
摘要:
目的：分析经验方解毒复正汤联合EGFR-TKIs对老年晚期肺癌患者临床疗效的影响及其对免疫功能和炎症因子水平的影响。方法：在广西中医药大学第一附属医院信息系统中检索2017年4月至2020年4月收治的IV期年龄大于70岁的肺癌患者，患者均为EGFR基因突变类型，均接受EGFR TKIs药物治疗，对照组单纯口服TKIs治疗，观察组在口服TKIs基础上联合解毒复正汤，前后共服药8周，观察两组患者服药前后生活质量，外周血免疫指标及炎性因子的表达水平，评估解毒复正汤是否与调节患者外周血免疫功能及炎症指标相关。结果：最终筛选出89例患者，其中对照组44例，观察组45例，8周服药前后对比两组患者，观察组患者的SGRQ生活质量、外周血炎症因子表达及免疫功能等方面均较对照组改善（P＜0.05）。结论：解毒复正汤联合EGFR-TKIs治疗可能通过提高患者的免疫功能，抑制外周炎性因子表达水平相关。结论：解毒复正汤及TKIs口服联合治疗模式较单纯TKIs口服治疗能更好改善老年肺癌患者生活质量，其机制可能与提高患者的免疫功能，抑制外周炎性因子表达水平相关。
Abstract:
Objective: To analyze the effect of Jiedu Fuzheng decoction combined with EGFR TKIs on the clinical efficacy of elderly patients with advanced lung cancer and its influence on immune function and inflammatory factors. Methods: From April 2017 to April 2020, we searched the information system of the First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine for patients with stage IV lung cancer older than 70 years old. All patients were EGFR gene mutation type and received EGFR TKIs drug treatment.The control group was treated with oral TKIs treatment, while the observation group was treated with Jiedu Fuzheng Decoction on the basis of oral administration of TKIs, the drug was administered for 8 weeks before and after. The quality of life, the expression of immune indexes and inflammatory factors in peripheral blood of the two groups were observed before and after treatment, and whether Jiedu Fuzheng decoction was related to the regulation of peripheral blood immune function and inflammatory indexes was evaluated. Results: 89 patients were finally screened out, including 44 cases in the control group and 45 cases in the observation group. The quality of life of SGRQ, the expression of inflammatory factors in peripheral blood and immune function of patients in the observation group were better than those in the control group before and after 8 weeks of medication (P < 0.05). Conclusion: Jiedu Fuzheng decoction combined with EGFR TKIs may improve the immune function and inhibit the expression of peripheral inflammatory factors. Jiedu Fuzheng decoction combined with TKIs oral therapy can improve the quality of life of elderly patients with lung cancer, and its mechanism may be related to improving the immune function and inhibiting the expression of peripheral inflammatory factors.

参考文献/References:

[1] 陈诺，石毓君. 肺癌发病、诊断及治疗相关研究进展[J]. 世界最新医学信息文摘，2018，18(6): 114-116. [2] 王辛华，孙凯. 肺癌发生危险因素的分析[J]. 中西医结合心血管病电子杂志，2018，6(5): 22-23. [3] 李琦玮，于明薇，王笑民. 癌毒理论研究现状[J]. 中医杂志，2015，56(4): 347-350. [4] 李春姗. 解毒扶正颗粒联合化疗治疗晚期非小细胞肺癌的临床研究[J]. 实用中西医结合临床，2014，14(12): 1-2. [5] 王家晓，张玉梅. 清毒扶正汤用于非小细胞肺癌化疗患者疗效观察[J]. 山东医药，2011，51(7): 86-87. [6] 原发性肺癌诊疗规范(2018年版)[J]. 肿瘤综合治疗电子杂志，2019，03: 100-120. [7] 王宁，刘硕，杨雷，等. 2018全球癌症统计报告解读[J]. 肿瘤综合治疗电子杂志，2019，01: 87-97. [8] Siegel R L, Miller K D, Jemal A. Cancer statistics, 2019[J]. CA: A Cancer Journal for Clinicians, 2019,69(1): 7-34. [9] Adamo A, Dal Collo G, Bazzoni R, et al. Role of mesenchymal stromal cell-derived extracellular vesicles in tumour microenvironment.[J]. Biochimica et Biophysica Acta, 2019, 18711. [10] Kalluri R. The biology and function of fibroblasts in cancer[J]. Nature Reviews Cancer, 2016, 16(9): 582-598. [11] 田建辉，刘海涛，刘嘉湘. 畅达“邪毒”出路提高肿瘤疗效[J]. 中医杂志，2018，59(3): 211-214.

备注/Memo

备注/Memo:
【收稿日期】2020-10-11 【基金项目】广西自然科学基金项目（2019JJB140156）；广西中医药大学自然科学研究课题项目（2018MS017）；广西卫生和计划生育委员会自筹经费课题（Z20170284）；广西中医药适宜技术开发与推广项目（GZSY20-22）。 【作者简介】姚菲，广西中医药大学第一附属医院副主任医师，研究方向为中医药对恶性肿瘤的发病机制。 【通信作者】石玮，广西中医药大学第一附属医院副主任医师，硕士生导师，研究方向为中医药对恶性肿瘤的发病机制。
更新日期/Last Update: 2021-01-07